Bellevue | Küsnacht, 05.06.2018. Bellevue Asset Management AG («Bellevue»), einer der grössten Finanzinvestoren im Bereich Biotechnologie, konnte für das Beratergremium der neuen Risikokapitalgesellschaft für qualifizierte Anleger BB Pureos Bioventures eine Reihe ausgewiesener Biotech-Experten gewinnen. Dazu zählen Dr. Thomas Hecht, Prof. Dr. Roger Nitsch, Prof. Dr. Dr. Klaus Strein, Dr. Mathieu Simon und Dallas Webb. Bellevue ist derzeit daran, Kapital für BB Pureos Bioventures zu beschaffen. Die neue Risikokapitalgesellschaft soll vorwiegend in private Unternehmen investieren, deren Schwerpunkt auf der Entwicklung innovativer …
Lesen Sie mehr »Tagesarchiv
Pressemitteilung Bellevue Asset Management: BB Biotech: Monthly Newes March 2016
Bellevue | Küsnacht, 07.04.2016 MARKET REVIEW: The Nasdaq Biotech Index (NBI) ended the month of March up +2.6% in USD. BB Biotech’s NAV was up +6.1% in USD, +2.1% in CHF and up +1.3% in EUR. BB Biotech’s share price was up +9.3% in USD, up +5.4% in CHF and +3.7% in EUR. In the month of March, BB Biotech outperformed its benchmark NBI, with both the NAV and even more so with the share price. However, as the share price continuously moved higher than the NAV, …
Lesen Sie mehr »Pressemitteilung Bellevue Asset Management AG: BB Biotech: Monthy News December 2015
Bellevue | Küsnacht, 11.01.2016. MARKET REVIEW The Nasdaq Biotech Index (NBI) ended the month of December up +1.3% in USD. BB Biotech’s NAV was up +0.2% in USD, -3.4% in CHF and down -3.0% in EUR. BB Biotech’s share price was up +2.6% in USD and lost -0.7% in EUR and -1.2% in CHF. 2015 was another year of outperformance for biotechnology versus general equity markets, with the Nasdaq Biotech Index NBI (+11.8% in USD) outperforming the S&P500 (+1.4% in USD) by +10%. BB Biotech …
Lesen Sie mehr »